Smith+Nephew Launches New Stemless Option in AETOS System

Smith+Nephew Introduces AETOS Stemless for Superior Shoulder Surgery

Smith+Nephew (LSE:SN, NYSE:SNN), a leading name in the field of medical technology, has announced a significant advancement with the introduction of a stemless option for its AETOS Shoulder System. This innovative implant has received 510(k) clearance from the United States Food & Drug Administration, marking an important milestone in anatomic shoulder arthroplasty.

Understanding the AETOS Stemless Advantage

The AETOS Stemless approach was designed to meet the rising demand for anatomic total shoulder replacements. It is tailored for efficiency, enabling surgeons to perform procedures with a smaller operating room footprint. This compact design not only streamlines the surgical process but is also focused on optimizing metaphyseal fixation and stability. Equipped with unique features such as an inlay collar and cruciate fins, along with a porous titanium coating, the AETOS Stemless promotes enhanced biological fixation.

Expansion of the AETOS Portfolio

Last year, the AETOS Shoulder System was launched with an elegant design and user-friendly experience in mind. The introduction of the new stemless option is a powerful addition, facilitating an easy transition between stemless and meta stem configurations. This flexibility allows surgical teams to tailor procedures according to patient needs, thereby promoting personalized care in shoulder surgeries.

Commitment to Patient-Centric Orthopaedics

Craig Gaffin, President of Global Orthopaedics for Smith+Nephew, expressed enthusiasm about the AETOS Stemless, stating that it represents a meaningful step forward in shoulder arthroplasty. He emphasized the company’s continued dedication to superior patient outcomes and the pursuit of innovative technologies that transform shoulder condition treatments. The AETOS Stemless device is expected to empower surgeons in providing the best potential recovery options for patients, embodying Smith+Nephew's goal of enabling people to live their ‘Life Unlimited’.

Market Growth in Total Shoulder Arthroplasty

Total shoulder arthroplasty is rapidly gaining traction in the orthopaedic field, with projections estimating around 250,000 procedures conducted annually in the United States by the near future. This growing segment showcases the increasing acceptance and necessity for effective shoulder replacement solutions.

Product Availability

The AETOS Shoulder System, including the newly launched AETOS Stemless, is now cleared for use in the United States and also holds approval for the Canadian market. This product joins Smith+Nephew’s comprehensive Upper Extremity portfolio that complements its leading-edge Sports Medicine shoulder repair and biologics solutions. The aim is to continuously enhance the offerings available to healthcare professionals worldwide.

About Smith+Nephew

Founded in Hull, UK in 1856, Smith+Nephew has evolved into a prominent medical technology company operating in more than 100 countries and generating a remarkable annual revenue of $5.5 billion in the latest reporting period. The firm focuses on the repair, regeneration, and replacement of soft and hard tissues, committing to its mission of restoring people’s self-belief and improving their quality of life through innovative technology. With a robust workforce of 18,000 employees, Smith+Nephew strives to make a positive impact on patients’ lives through its diverse product portfolio across three key sectors: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.

Frequently Asked Questions

What is the AETOS Stemless?

The AETOS Stemless is a new implant option within the AETOS Shoulder System designed for anatomic total shoulder arthroplasty, offering a smaller operating room footprint.

Why is the AETOS Stemless significant?

This new option addresses the increasing demand for shoulder replacement procedures and enhances surgical efficiency while promoting better patient fixation through innovative design features.

Who is the manufacturer of the AETOS Stemless?

Smith+Nephew, a global medical technology company headquartered in the UK, manufactures the AETOS Stemless implant.

What are the unique features of the AETOS Stemless?

It includes an inlay collar, cruciate fins, and a porous titanium coating that collectively enhance biological fixation and surgical stability.

Where is the AETOS Stemless available?

Currently, the AETOS Stemless is cleared for use in the United States and approved for use in Canada, increasing its accessibility to healthcare professionals.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.